Arete Wealth Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,450	Closed	-$128K	–	359
2025 Q4	$128K	Sell	16,450 -3,000	-15%	-$21.7K	0.01%	738
2025 Q3	$148K	Hold	19,450	–	–	0.01%	740
2025 Q2	$174K	Sell	19,450 -750	-4%	-$6.99K	0.01%	695
2025 Q1	$152K	Hold	20,200	–	–	0.01%	686
2024 Q4	$152K	Buy	20,200 +8,150	+68%	+$61.9K	0.01%	711
2024 Q3	$92K	Sell	12,050 -10,150	-46%	-$77.2K	0.01%	675
2024 Q2	$137K	Buy	+22,200	New	+$123K	0.01%	681
2024 Q1	–	Sell	-22,550	Closed	-$135K	–	412
2023 Q4	$135K	Sell	22,550 -750	-3%	-$4.35K	0.01%	699
2023 Q3	$165K	Buy	23,300 +9,150	+65%	+$65.7K	0.03%	446
2023 Q2	$100K	Sell	14,150 -9,823	-41%	-$78.8K	0.01%	631
2023 Q1	$200K	Buy	23,973 +350	+1%	+$3.37K	0.02%	580
2022 Q4	$271M	Buy	+23,623	New	+$295K	0.02%	484